PROVIDER PROFILE · NPI 1164587226

Molly MoloznikP.A.-C

PRACTICEPALO VERDE HEMATOLOGY ONCOLOGY,LTD.See all providers at this practice →

Physician AssistantGlendale, AZI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

693

Unique beneficiaries

—

Total services

1,274

Distinct HCPCS

Medicare payment

$42K

Peer benchmark

Total Medicare services vs. 2,639 Physician Assistant providers in AZ — top quintile (cohort median 341).

PRESCRIBING · PART D · 2024

Total Rx claims

331

Beneficiaries

—

Total drug cost

$292K

Distinct drugs

Brand share

13.3%

Top prescribed drugs

Ketoconazole78 claims

Clobetasol Propionate53 claims

Triamcinolone Acetonide35 claims

Fluorouracil24 claims

Tretinoin22 claims

QUALITY · MIPS · 2024

Final MIPS score

90.0

Quality

96.9

Cost

70.8

Improvement activities

40.0

Promoting interop.

0.0

Payment adjustment

0.63%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$2K

Payment records

120

By payment type

Food and Beverage$2K

REFERRAL NETWORK

Where Molly Moloznik's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 0 inbound referrers · 5 outbound destinations.

Receives referrals from

Inbound — who sends patients here

No inbound pairs above the suppression threshold.

Refers patients to

Outbound — where patients go next

Physician	Patients	Visits
Sonora Quest Laboratories Llc Clinical Laboratory · Phoenix, AZ	44	81
HIATT, KIM	24	28
ASL-DEN LLC	23	32
Laboratory Corporation Of America Clinical Laboratory · Phoenix, AZ	17	30
Amena Deluca Dermatology · Phoenix, AZ	12	18

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history